SCHEMBL4977208

SCHEMBL4977208

CC(C)(C)N(C(=O)O)C1CC1(Cc1ccccn1)S(N)(=O)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HSD11B1 P28845 2/20 0.36
LTB4R Q15722 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
GAA P10253 1/20 0.34
CA2 P00918 3/20 0.34
CA1 P00915 2/20 0.34
KMT2A Q03164 1/20 0.34
CYP1A2 P05177 1/20 0.34
P2RX7 Q99572 1/20 0.34
CA5A P35218 1/20 0.34
CA7 P43166 1/20 0.34
CA5B Q9Y2D0 1/20 0.34
CXCR3 P49682 1/20 0.34
GRIN2B Q13224 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4981384 0.79 ALDH1A1 (0.36) ALDH1A1KDM4EHSD11B1SLC6A2GAA
SCHEMBL4983526 0.78 EPHX2 (0.35) ALDH1A1GAA
SCHEMBL4978747 0.76 RIPK1 (0.34) KMT2A
SCHEMBL4977504 0.75 TAS2R14 (0.38) ALDH1A1CA2CA1KMT2ACA5A
SCHEMBL4975355 0.74 MEN1 (0.36) ALDH1A1HSD11B1SLC6A2SLC6A4SLC6A3
SCHEMBL4984750 0.72 MEN1 (0.36) ALDH1A1GAACA2CA1KMT2A
SCHEMBL4977363 0.71
SCHEMBL4977212 0.70 L3MBTL1 (0.38) ALDH1A1KDM4EGAACA2CA1
SCHEMBL4979138 0.69
SCHEMBL4977210 0.67 ALDH1A1 (0.38) ALDH1A1KDM4EGAAKMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1505945-B1 SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2008-11-05 EP disclosed
US-6878722-B2 Substituted cycloalkyl P1′ hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-12 US disclosed
US-20040077551-A1 Substituted cycloalkyl P1' hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077551-A1 Substituted cycloalkyl P1' hepatitis C virus inhibitors HAVCR2, ANPEP, ENPEP ALDH1A1 2672/4885KDM4E 4299/4885HSD11B1 2432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.